TWI600654B - 用於治療寄生蟲疾病之化合物及組合物 - Google Patents

用於治療寄生蟲疾病之化合物及組合物 Download PDF

Info

Publication number
TWI600654B
TWI600654B TW102141950A TW102141950A TWI600654B TW I600654 B TWI600654 B TW I600654B TW 102141950 A TW102141950 A TW 102141950A TW 102141950 A TW102141950 A TW 102141950A TW I600654 B TWI600654 B TW I600654B
Authority
TW
Taiwan
Prior art keywords
pyridine
pyrazolo
phenyl
carboxamide
methyl
Prior art date
Application number
TW102141950A
Other languages
English (en)
Chinese (zh)
Other versions
TW201429967A (zh
Inventor
雅那伯 夏特吉
艾德維特 奈葛雷
普拉蘇納 帕拉賽利
拉維恩德 雷迪 康卓狄
梁世勇
波那伯 米席拉
羅伯 摩洛
傑森 湯瑪士 羅蘭
維琳 珊卓拉 沈
賽門 奧利佛
麗英 喬瑟琳 陳
布萊恩K S 楊
鄒彬
凡卡塔塔艾 布魯
Original Assignee
艾姆公司
諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾姆公司, 諾華公司 filed Critical 艾姆公司
Publication of TW201429967A publication Critical patent/TW201429967A/zh
Application granted granted Critical
Publication of TWI600654B publication Critical patent/TWI600654B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW102141950A 2012-11-19 2013-11-18 用於治療寄生蟲疾病之化合物及組合物 TWI600654B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728018P 2012-11-19 2012-11-19
US201361847860P 2013-07-18 2013-07-18

Publications (2)

Publication Number Publication Date
TW201429967A TW201429967A (zh) 2014-08-01
TWI600654B true TWI600654B (zh) 2017-10-01

Family

ID=49667630

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102141950A TWI600654B (zh) 2012-11-19 2013-11-18 用於治療寄生蟲疾病之化合物及組合物

Country Status (19)

Country Link
US (3) US9556169B2 (en:Method)
EP (1) EP2925757B1 (en:Method)
JP (1) JP6298472B2 (en:Method)
CN (1) CN105164124B (en:Method)
AR (1) AR093532A1 (en:Method)
CY (1) CY1119727T1 (en:Method)
DK (1) DK2925757T3 (en:Method)
ES (1) ES2655030T3 (en:Method)
HR (1) HRP20171998T1 (en:Method)
HU (1) HUE037600T2 (en:Method)
LT (1) LT2925757T (en:Method)
ME (1) ME03042B (en:Method)
PL (1) PL2925757T3 (en:Method)
PT (1) PT2925757T (en:Method)
RS (1) RS56720B1 (en:Method)
SI (1) SI2925757T1 (en:Method)
TW (1) TWI600654B (en:Method)
UY (1) UY35146A (en:Method)
WO (1) WO2014078802A1 (en:Method)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
JP2019507122A (ja) 2016-01-21 2019-03-14 ノバルティス アーゲー クリプトスポリジウム症の治療のための化合物および組成物
TWI696615B (zh) * 2016-05-05 2020-06-21 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-三唑及雜芳基-三唑化合物
EP3484886B1 (en) * 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
BR112019007594A2 (pt) * 2016-10-13 2019-07-02 Loyola University Of Chicago método para bloquear a transmissão do parasita da malária
MA52337A (fr) 2017-03-01 2021-03-03 Anacor Pharmaceuticals Inc Nouveaux analogues d'oxaborole et utilisations de ces derniers
AU2018240031B2 (en) 2017-03-20 2022-07-14 President And Fellows Of Harvard College Compounds and methods for the treatment of parasitic diseases
KR20250084983A (ko) 2017-03-27 2025-06-11 하이드로-퀘벡 전해질 조성물에서 또는 전극 첨가제로서 사용하기 위한 염
CN107037148B (zh) * 2017-04-07 2019-11-19 上海药明康德新药开发有限公司 卤泛曲林的高效液相检测方法
JOP20190278A1 (ar) 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
US11628593B2 (en) 2017-10-02 2023-04-18 Dal-Tile, Llc Method for manufacturing an engineered stone and an engineered stone
KR20250044476A (ko) * 2018-07-09 2025-03-31 베링거잉겔하임베트메디카게엠베하 구충성 헤테로시클릭 화합물
GB201811695D0 (en) * 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
UY38540A (es) * 2019-01-14 2020-08-31 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
KR20220002890A (ko) 2019-03-19 2022-01-07 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물
CA3141905A1 (en) 2019-06-07 2020-12-10 Elanco Tiergesundheit Ag Bicyclic derivatives for treating endoparasites
RU2019123849A (ru) * 2019-07-29 2021-02-01 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Ингибиторы фактора ингибирования миграции макрофагов
KR20230028268A (ko) 2020-05-29 2023-02-28 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 헤테로시클릭 화합물
US12018024B2 (en) * 2020-10-14 2024-06-25 Novartis Ag Compounds and compositions for the treatment of cryptosporidiosis
WO2023275590A1 (en) 2021-06-29 2023-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Detection of phosphoinositides in blood cells as a biomarker for alpha synuclein associated pathologies and a method of treatment of parkinson's disease and the related neurodegenerations
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
CN118339164A (zh) 2021-11-01 2024-07-12 勃林格殷格翰动物保健有限公司 驱虫吡咯并哒嗪化合物
CA3181279A1 (en) * 2022-03-24 2023-09-24 Bloom Energy Corporation Fuel cell stack assembly including heat sink inserts
US12338188B2 (en) 2022-06-30 2025-06-24 Dal-Tile, Llc Method for manufacturing a decorative element comprising an engineered stone and a decorative element comprising an engineered stone
US12358305B2 (en) 2022-06-30 2025-07-15 Dal-Tile, Llc Method for manufacturing a decorative element comprising an engineered stone and a decorative element comprising an engineered stone
WO2024006974A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024196989A1 (en) * 2023-03-20 2024-09-26 University Of Central Florida Research Foundation, Inc. Anti-malarial therapy
AR132354A1 (es) * 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados de pirazolo[1,5-a]piridina
EP4667535A1 (en) 2024-06-17 2025-12-24 SilOriX GmbH Nonlinear optical dyes with improved stability

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219218A1 (en) * 2004-07-16 2007-09-20 Schering Corporation Compounds for the treatment of inflammatory disorders
WO2011006143A2 (en) * 2009-07-09 2011-01-13 Irm Llc Compounds and compositions for the treatment of parasitic diseases

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034866A1 (en) 1995-05-01 1996-11-07 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors
DK0915880T3 (da) 1996-07-24 2008-02-11 Bristol Myers Squibb Pharma Co Azolotriaziner og pyrimidiner
CA2295239A1 (en) 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
JP2001139575A (ja) 1999-11-15 2001-05-22 Fujisawa Pharmaceut Co Ltd 新規ピラゾロピリジン誘導体
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0002312D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
US7105550B2 (en) * 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
EP1276742B1 (en) 2000-04-28 2004-06-09 Glaxo Group Limited Process for the preparation of pyrazolopyridine derivatives
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
AUPR916301A0 (en) 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
JP4500055B2 (ja) 2002-04-23 2010-07-14 塩野義製薬株式会社 ピラゾロ[1,5−a]ピリミジン誘導体およびそれを含有するNAD(P)Hオキシダーゼ阻害剤
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
ATE370139T1 (de) 2002-09-17 2007-09-15 Lilly Co Eli Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR20070032787A (ko) * 2004-07-16 2007-03-22 쉐링 코포레이션 염증 질환 치료용 히단토인 유도체
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
EP1797054A2 (en) 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
EP1804801A2 (en) 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
CA2586259A1 (en) 2004-11-08 2006-05-11 Banyu Pharmaceutical Co., Ltd. Novel fused imidazole derivative
EP1828185B1 (en) * 2004-12-21 2009-05-06 SmithKline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
EP1832588A4 (en) 2004-12-28 2009-09-02 Takeda Pharmaceutical CONDENSED IMIDAZOLE COMPOUND AND ITS USE
US7713975B1 (en) 2005-01-12 2010-05-11 Alcon, Inc. 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
TW200800213A (en) 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Pgd2受容体アンタゴニスト活性を有するスルホンアミド誘導体
US20070129364A1 (en) 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
KR20080074161A (ko) 2005-12-08 2008-08-12 노파르티스 아게 EPHB 및 VEGFR2 키나아제 억제제로서의피라졸로[1,5-a]피리딘-3-카르복실산
WO2007086080A2 (en) 2006-01-30 2007-08-02 Glenmark Pharmaceuticals Limited NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
CA2643802A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP5352452B2 (ja) 2006-06-06 2013-11-27 メディシノバ, インコーポレイテッド 置換ピラゾロ[1,5−a]ピリジン化合物およびその使用方法
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
WO2008033408A2 (en) 2006-09-12 2008-03-20 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
AU2007316417B2 (en) 2006-11-06 2013-08-22 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Fgfrインヒビターとしての二環式ヘテロ環式化合物
JP2010516774A (ja) 2007-01-26 2010-05-20 アイアールエム・リミテッド・ライアビリティ・カンパニー マラリア原虫関連疾患を処置するためのキナーゼ阻害剤としてのプリン化合物および組成物
US8088385B2 (en) 2007-06-18 2012-01-03 University Of Louisville Research Foundation Inc. PFKB3 inhibitor for the treatment of a proliferative cancer
AU2008273050A1 (en) 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
EA017250B1 (ru) 2007-07-19 2012-11-30 Х. Лундбекк А/С 5-членные гетероциклические амиды и их применение для модуляции рецептора p2x
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AR070487A1 (es) 2008-02-28 2010-04-07 Novartis Ag Derivados de 3- metil- imidazo -( 1,2-b)- piridazina
US8507501B2 (en) * 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
ES2548135T3 (es) 2008-05-13 2015-10-14 Novartis Ag Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
JP2009298710A (ja) 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾ[1,2−b]ピリダジン誘導体含有医薬組成物
AU2009267137A1 (en) 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
US8518911B2 (en) 2008-08-05 2013-08-27 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyridines as MARK inhibitors
CA2732520A1 (en) 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN102223798A (zh) * 2008-09-24 2011-10-19 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010064020A1 (en) 2008-12-04 2010-06-10 Proximagen Ltd. Imidazopyridine compounds
WO2010074586A1 (en) 2008-12-23 2010-07-01 Pathway Therapeutics Limited Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives and their use in cancer therapy
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
WO2010108187A2 (en) 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
AU2010226490A1 (en) 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase
WO2010117787A2 (en) 2009-03-30 2010-10-14 The Brigham And Women's Hospital, Inc. Inhibiting eph b-3 kinase
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
RU2421455C2 (ru) 2009-07-14 2011-06-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ 7-АРИЛКАРБАМОИЛ-6-БЕНЗОИЛ-2-МЕТИЛ-3-ФЕНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИН-5-КАРБОКСИЛАТОВ
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TW201113286A (en) 2009-09-03 2011-04-16 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
JP2013506624A (ja) 2009-09-23 2013-02-28 アミラ ファーマシューティカルズ,インク. 5−リポキシゲナーゼのインドリジンインヒビター
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
EP2920177A1 (en) 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219218A1 (en) * 2004-07-16 2007-09-20 Schering Corporation Compounds for the treatment of inflammatory disorders
WO2011006143A2 (en) * 2009-07-09 2011-01-13 Irm Llc Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
WO2014078802A1 (en) 2014-05-22
RS56720B1 (sr) 2018-03-30
DK2925757T3 (en) 2018-01-15
CN105164124A (zh) 2015-12-16
EP2925757A1 (en) 2015-10-07
UY35146A (es) 2014-06-30
PL2925757T3 (pl) 2018-06-29
EP2925757B1 (en) 2017-10-04
US20180230145A1 (en) 2018-08-16
US9556169B2 (en) 2017-01-31
JP2016505529A (ja) 2016-02-25
JP6298472B2 (ja) 2018-03-20
ME03042B (me) 2018-10-20
PT2925757T (pt) 2018-01-09
HUE037600T2 (hu) 2018-09-28
TW201429967A (zh) 2014-08-01
AR093532A1 (es) 2015-06-10
US20150344471A1 (en) 2015-12-03
CN105164124B (zh) 2017-03-15
LT2925757T (lt) 2017-12-27
US20160333012A1 (en) 2016-11-17
ES2655030T3 (es) 2018-02-16
HRP20171998T1 (hr) 2018-02-09
CY1119727T1 (el) 2018-06-27
SI2925757T1 (en) 2018-01-31
US9926314B2 (en) 2018-03-27

Similar Documents

Publication Publication Date Title
TWI600654B (zh) 用於治療寄生蟲疾病之化合物及組合物
JP7088983B2 (ja) キナーゼ阻害剤としてのビアリールアミド化合物
CN110582491B (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN105992768B (zh) 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
RU2720237C2 (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
TWI583681B (zh) 胺基嘧啶基化合物
CN113227068A (zh) Glp-1r激动剂及其用途
TWI440639B (zh) 作為trpv1調節劑之四氫-嘧啶并氮呯類
CN116942663A (zh) 用于治疗hbv的化合物
WO2014078813A1 (en) Compounds and compositions for the treatment of parasitic diseases
CN105682656A (zh) 调节法尼醇x受体的组合物和方法
TW201630907A (zh) TGFβR拮抗劑
TW202237600A (zh) 雙環衍生物
CN112955142A (zh) 官能化杂环化合物作为抗病毒剂
CN107001329A (zh) 作为激酶抑制剂的化合物和组合物
WO2019189555A1 (ja) 複素環化合物
CN115151550A (zh) 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)调节剂及其用途
CN117069724A (zh) 稠环化合物、药物组合物和应用
US8871754B2 (en) Compounds and compositions for the treatment of parasitic diseases
CN107759620B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
JP2023545452A (ja) クリプトスポリジウム症の治療のための化合物及び組成物
WO2023165574A1 (zh) 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
HK40046602B (zh) 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
HK1241857A1 (en) Aminopyrimidinyl compounds as jak inhibitors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees